To combat the increasing incidence of healthcare workplace violence, hospitals must “identify patients at risk for intentional harm to self or others, identify environmental safety risks for such patients, and provide education and training for staff and volunteers” so that workers can deliver care in a safe setting, the Centers for Medicaid and Medicare Services’ (CMS) Quality, Safety, and Oversight Group (QSOG) and Survey and Operations Group (SOG) said in a November 2022 memo.
On August 5, 2022, the U.S. Food and Drug Administration approved darolutamide (Nubeqa®) in combination with docetaxel in adults with metastatic hormone-sensitive prostate cancer. The approval was based on clinical trial findings demonstrating that the agent improved overall survival and significantly delayed time to pain progression compared to placebo.
U.S. Senators Ben Cardin (D-MD) and Amy Klobuchar (D-MN) and U.S. Representatives Debbie Wasserman Schultz (D-FL), Brian Fitzpatrick (R-PA), and Mark DeSaulnier (D-CA) introduced the Comprehensive Cancer Survivorship Act in December 2022 to address gaps in survivorship care and formulate standards to improve quality of cancer care and navigation needs of survivors.
Most patients at high risk for developing pancreatic cancer whose disease was found while participating in a screening program were diagnosed with early-stage cancers, according to study findings published in the Journal of Clinical Oncology.
To address and achieve equity in health care, in fall 2022 the National Institute of Nursing Research (NINR) began offering new funding opportunities for research studies aligned with the scientific framework outlined in the institute’s 2022–2026 strategic plan. The grants are available cyclically with three application periods per year.
In your day-to-day conversations with patients, colleagues, or even friends and family at home, are you merely hearing what others tell you or are you actively listening to them? When we actively listen to what someone is saying, we intreat curiosity about their words and the emotions they are communicating with their tone and body language. Active listening engages a whole-person connection, whereas passive listening relies on the brain’s ability to catch the main points of a conversation.
In a December 2022 statement, Monica M. Bertagnolli, MD, National Cancer Institute director, announced that she was diagnosed with hormone receptor-positive, HER2-negative breast cancer and that her prognosis is favorable. She said she is enrolled in a clinical trial centered around her diagnosis to contribute to the cancer knowledge base and advance care.
On January 19, 2023, the U.S. Food and Drug Administration approved zanubrutinib (Brukinsa®) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
On January 19, 2023, the U.S. Food and Drug Administration granted accelerated approval to tucatinib (Tukysa®) in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Sick. Americans are literally sick of the financial burden vulnerable patients endure because of high out-of-pocket, healthcare-related costs. The complicated and convoluted issue has no easy solution.